NCT01678794View on ClinicalTrials.gov

CR Aim #2 - AT1 Receptor Blockade & ACE Inhibition Effect on Humoral Function

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

June 29, 2016

Study Completion Date

June 29, 2016

Conditions
Cardiorenal Syndrome (CRS)
Interventions
DRUG

Candesartan

4 mg once a day up to 13 day. dose will be doubled every 14-18 days as tolerated to a goal of 16 mg a day or highest dose tolerated

DRUG

Placebo

4 mg once a day up to 13 day. dose will be doubled every 14-18 days as tolerated to a goal of 16 mg a day or highest dose tolerated

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Mayo Clinic

OTHER

NCT01678794 - CR Aim #2 - AT1 Receptor Blockade & ACE Inhibition Effect on Humoral Function | Biotech Hunter | Biotech Hunter